Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma
出版年份 2016 全文链接
标题
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 108, Issue 8, Pages djw030
出版商
Oxford University Press (OUP)
发表日期
2016-04-09
DOI
10.1093/jnci/djw030
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sunitinib rechallenge in two advanced GIST patients after third-line anti-tyrosine kinase therapy.
- (2017) E. Fumagalli et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy
- (2015) M. Paez-Ribes et al. CLINICAL CANCER RESEARCH
- A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer
- (2015) Laurence Albiges et al. EUROPEAN UROLOGY
- Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases
- (2015) Han-Sin Jeong et al. JNCI-Journal of the National Cancer Institute
- Investigation of the Lack of Angiogenesis in the Formation of Lymph Node Metastases
- (2015) Han-Sin Jeong et al. JNCI-Journal of the National Cancer Institute
- Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy
- (2015) Terence C. Tang et al. NEOPLASIA
- Impact of Metronomic UFT/Cyclophosphamide Chemotherapy and Antiangiogenic Drug Assessed in a New Preclinical Model of Locally Advanced Orthotopic Hepatocellular Carcinoma
- (2015) Terence C. Tang et al. NEOPLASIA
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma
- (2014) M. Nowosielski et al. NEUROLOGY
- Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy
- (2013) N S Vasudev et al. BRITISH JOURNAL OF CANCER
- Drug rechallenge and treatment beyond progression—implications for drug resistance
- (2013) Elizabeth A. Kuczynski et al. Nature Reviews Clinical Oncology
- Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
- (2013) Krastan B. Blagoev et al. Cell Reports
- Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
- (2013) Tom Donnem et al. Cancer Medicine
- Sorafenib rechallenge in patients with metastatic renal cell carcinoma
- (2012) Masahiro Nozawa et al. BJU INTERNATIONAL
- Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
- (2012) Hannah van Malenstein et al. CANCER LETTERS
- Insights into cancer metastasis from a clinicopathologic perspective: Epithelial-Mesenchymal Transition is not a necessary step
- (2012) Michael Herman Chui INTERNATIONAL JOURNAL OF CANCER
- Tumor budding in colorectal carcinoma: time to take notice
- (2012) Bojana Mitrovic et al. MODERN PATHOLOGY
- Classifying collective cancer cell invasion
- (2012) Peter Friedl et al. NATURE CELL BIOLOGY
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence
- (2011) Wolfgang Wick et al. Current Neurology and Neuroscience Reports
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression
- (2011) Liang Zhang et al. PLoS One
- Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression
- (2010) Rong-Xin Chen et al. MOLECULAR BIOLOGY REPORTS
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- (2010) H. J. Hammers et al. MOLECULAR CANCER THERAPEUTICS
- Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT
- (2009) Andrew Dennis Smith et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Sorafenib for Metastatic Renal Cancer
- (2008) Rachel P. Riechelmann et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search